Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001991329 | SCV002282690 | uncertain significance | not provided | 2022-07-19 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 280 of the SP7 protein (p.Arg280Leu). This variant is present in population databases (rs200582631, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with SP7-related conditions. ClinVar contains an entry for this variant (Variation ID: 1495322). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C35"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome Diagnostics Laboratory, |
RCV002276978 | SCV002565037 | uncertain significance | Osteogenesis imperfecta | 2020-04-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004045466 | SCV004957735 | uncertain significance | not specified | 2022-08-17 | criteria provided, single submitter | clinical testing | The c.839G>T (p.R280L) alteration is located in exon 3 (coding exon 2) of the SP7 gene. This alteration results from a G to T substitution at nucleotide position 839, causing the arginine (R) at amino acid position 280 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV001991329 | SCV005408335 | uncertain significance | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | BP4, PM2 |